Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as one of the 12 Stocks that Will Bounce Back according to Wall Street Analysts, with LifeSci Capital reiterating a Buy rating and a price target of $110 on December 11. Piper Sandler also noted the company’s potential for transformational growth in 2026.

Piper Sandler expressed confidence in Soleno Therapeutics, Inc. (NASDAQ:SLNO) and other commercial-stage biotech companies, highlighting their plans for drug launches and growth potential in the industry.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced on January 5 that results from a pivotal study of VYKAT XR were published in the Journal of Clinical Endocrinology and Metabolism, demonstrating the drug’s efficacy and safety for treating hyperphagia in individuals with Prader-Willi syndrome.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a biopharmaceutical company focused on developing innovative therapeutics for rare diseases. While the company shows investment potential, other AI stocks may offer greater upside and less risk according to analysts.

For more investment opportunities, check out the 10 Best US Penny Stocks to Buy and the 10 Best New Penny Stocks to Invest In. This article is originally published on Insider Monkey.

Read more at Yahoo Finance: Soleno Therapeutics (SLNO) Among Stocks That Will Bounce Back According to Analysts